Brentuximab Vedotin is an antibody-drug conjugate (ADC), currently in clinical trials for single-agent clinical trials, a pivotal trial for relapsed and refractory hodgkin lymphoma, and a phase II
Abstral, developed by Orexo is a new, rapidly disintegrating, sublingual formulation of fentanyl, a long-established opioid used for the management of episodes of breakthrough pain experienced by cancer
The candidate is produced through a proprietary process using a new growth environment that promotes faster maturation than chicken eggs, the standard environment since 1943. The phase II
BTG has a licensing agreement with Beacon Pharmaceuticals for the marketing of DigiFab in Europe, and Beacon has sub-licensed DigiFab distribution in Switzerland to Proreo Pharma. DigiFab has
Situated about 20 kms from the national capital, New Delhi, Unichem’s Ghaziabad facility enjoys the privileges of efficient infrastructure, that is highly conducive for industrial development. Ghaziabad has
Itochu acts in partnership with Optigenex under a long-term exclusive supply and trademark licensing agreement, to market AC-11 bulk material and consumer products containing AC-11 under sublicenses in
For Q4 2009, Pfizer posted net income of $767m, an increase of 188% compared to $266m in the prior-year quarter, and reported diluted EPS of $0.10, an increase
ISC’s facility consists of separate suites for development and production of different cell types from the company’s proprietary human parthenogenic stem cell (hpSC) technology. The company has established
The company said that the needles of pre-filled syringes, penetrating the needle shield, put sterility of needle and product at risk, as well as endanger medical staff. A
The company said that the combination reduces the accumulation of retained species on the membrane surface, which allows for increased transmission of the target molecule. The PallSep Biotech
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.